1-20 of 117
Ajay K. Nooka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S. Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez-Otero
Journal: Blood
Blood blood.2024024582.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Clinical Trials & Observations
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred Garfall
Journal: Blood
Blood blood.2023023616.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

Heme Attenuates T Cell Exhaustion and Drives Effector Function: Implications for Immune and Adoptive T Cell Therapy

Pulkit Gupta, Heather Lin, Remya Nair, Ruby Freeman, Dejah Blake, Kiran Lakhani, Doris R. Powell, Sagar Lonial, Benjamin G. Barwick, Ajay K. Nooka, Sarwish Rafiq, Mala Shanmugam
Journal: Blood
Blood (2023) 142 (Supplement 1): 6807.
https://doi.org/10.1182/blood-2023-186634
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption

Ruben Niesvizky, Bertrand Arnulf, Mohamad Mohty, Ajay K. Nooka, Salomon Manier, Michael Tomasson, Nizar J Bahlis, Donald Irby, Jennifer Hibma, Andrea Viqueira, Eric Leip, Alexander Lesokhin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3384.
https://doi.org/10.1182/blood-2023-182166
Published: 2023
Journal Articles

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Ellen Marin, Sara Scott, Kathryn Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
Journal: Blood
Blood (2023) 142 (Supplement 1): 2008.
https://doi.org/10.1182/blood-2023-189878
Published: 2023
Journal Articles

Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies

Asya Varshavsky-Yanovsky, Yogesh Jethava, Don A. Stevens, Ajay K. Nooka, Patrick J. Stiff, Isabel Perez-Cruz, Eric Leip, Alexander Lesokhin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3333.
https://doi.org/10.1182/blood-2023-181951
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Carlyn Tan, Neha Korde, Andriy Derkach, Malin Hultcrantz, Kylee H Maclachlan, Hani Hassoun, Sham Mailankody, Urvi A Shah, Sridevi Rajeeve, Dhwani Patel, Alexander Lesokhin, Oscar Boutros Lahoud, Gunjan L. Shah, Michael Scordo, David Chung, Heather Landau, Sergio A. Giralt, Craig C. Hofmeister, Jonathan L. Kaufman, Ajay K. Nooka, Saad Z Usmani, Sagar Lonial, Nisha S. Joseph
Journal: Blood
Blood (2023) 142 (Supplement 1): 1996.
https://doi.org/10.1182/blood-2023-190279
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Rachid Baz, Paula Rodriguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Ajay K. Nooka, Luciano Costa, Noopur S. Raje, Ingerid Weum Abrahamsen, Michel Delforge, Usama Gergis, Douglas W. Sborov, Sergio A. Giralt, Marc S. Raab, Tadao Ishida, Asya Varshavsky-Yanovsky, Taewoong Choi, Larry D. Anderson, Jr., Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Yi Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4879.
https://doi.org/10.1182/blood-2023-174477
Published: 2023
Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise
Journal: Blood
Blood (2023) 142 (Supplement 1): 4699.
https://doi.org/10.1182/blood-2023-181783
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial
Journal: Blood
Blood (2023) 142 (Supplement 1): 4764.
https://doi.org/10.1182/blood-2023-190871
Published: 2023
Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3386.
https://doi.org/10.1182/blood-2023-180761
Published: 2023
Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka
Journal: Blood
Blood (2023) 142 (Supplement 1): 647.
https://doi.org/10.1182/blood-2023-187339
Published: 2023
Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2013.
https://doi.org/10.1182/blood-2023-181905
Published: 2023
Journal Articles

Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs

Julie Barberio, Timothy L. Lash, Ajay K. Nooka, Ashley I. Naimi, Rachel E. Patzer, Christopher Kim
Journal: Blood
Blood (2022) 140 (Supplement 1): 4267–4268.
https://doi.org/10.1182/blood-2022-159713
Published: 2022
Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Hope Robinson, Nancy Villa, David L Jaye, Ajay K. Nooka, Alyssa Duffy, Samuel McCachren, Julia Manalo, Jeffrey M. Switchenko, Ava Horvat, Vaunita C Parihar, Jingjing Gong, Yan Liang, Geoffrey Smith, Vikas A Gupta, Lawrence H. Boise, Jonathan L. Kaufman, Craig C Hofmeister, Nisha Joseph, Sagar Lonial, Kavita Dhodapkar, Madhav Dhodapkar
Journal: Blood
Blood (2022) 140 (Supplement 1): 244–245.
https://doi.org/10.1182/blood-2022-169558
Published: 2022
Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Ajay K. Nooka, Adam Cohen, Hans C. Lee, Ashraf Z. Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward Libby, Maria Chaudhry, Malin Hultcrantz, Martin Kortuem, Paul G. Richardson, Rakesh Popat, Douglas W. Sborov, Shawn Hakim, Eric Lewis, Bharat Bhushan, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sagar Lonial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7301–7303.
https://doi.org/10.1182/blood-2022-164877
Published: 2022
Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister
Journal: Blood
Blood (2022) 140 (Supplement 1): 5988–5990.
https://doi.org/10.1182/blood-2022-170778
Published: 2022